Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...
Disclaimer: The information provided here is latest and updated as available from India Post, but the users are advised to verify information with the respective Postal Office before using the ...
News and insight from the business world.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback